Galapagos (Euronext & NASDAQ: GLPG) is a commercial-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. In partnership with the French Medicinal Chemistry Society SCT, has decided to award a talented team of researchers contributing to a scientific discovery and /or substantial therapeutic innovation. Specific emphasis will be given to the notion of drug discovery chemistry where combined disciplines, among for example molecular modeling, in silico approaches, chemistry, chemical-biology, biology or ADMET can contribute to the achievement of the team’s objectives. This contribution may arise from the any phase of research and the aim of this prize is to nominate a talented team.
Opening dates : 15 December 2022 – 15 February 2023 (at midnight)
The SCT and Galapagos are proud to announce that the first Galapagos Award for Drug Discovery Chemistry has been attributed to the interdisciplinary project from BioVersys (Dr. Olivier Defert, candidate team representative), Université de Lille (Pr. Nicolas Willand), Institut Pasteur de Lille/Inserm (Dr. Alain Baulard), and GSK (Dr. Modesto Remuinan).
Starting from early academic and Biotech research their work culminated in the identification of a novel antituberculosis agent, BVL-GSK098, as a clinical candidate targeting a novel transcriptional repressor, called "VirS". In line Galapagos’ mission to develop first-in-class medicines based on the discovery of novel targets we are happy to acknowledge the contribution of Olivier Defert’s team to the progress of modern medicinal chemistry and drug discovery innovation.The SCT thanks Galapagos for this partnership to acknowledge excellence in interdisciplinary medicinal chemistry for the benefit of patients. The award has been presented at the 2022 EFMC-ISMC in Nice.
The candidate’s team should be based in Europe and the members have to accomplish their duty as SCT member by paying their membership by credit card on the SCT website to be eligible.
The “Galapagos Award” jury members select the laureate among the candidates.
By accepting the award, the laureate team representative agrees to present a plenary lecture at the next RICT meeting or a SCT (co)-organized event in case RICT meeting cannot take place.
Candidacies should be emailed to the SCT secretary, as well as to the SCT president, .
The candidates or candidate team representative should provide a short pdf document (font: Arial 12, space between lines: 1.15) describing their project with an emphasis of the integration of the various disciplines contributing to science, including the state of art, the context and the exceptional added value of the integrative approach in medicinal chemistry, the potential impact on the downstream phases, the perspectives.
This has to be accompanied with the bibliographic references.
In addition, a short CV of the team members should be added.
The total length of this document (Contribution+Refs+CV) should not exceed 10 printed pages.
Galapagos Award for Drug Discovery Chemistry Recipients